Tuberculosis (TB) epidemiology in Israel is similar to that reported from other industrialised countries where most patients are foreign-born. O B J E C T I V E S : To assess TB case fatality rate (CFR) and mortality trends during treatment and to identify risk factors associated with mortality. D E S I G N : Retrospective cohort study of all TB patients in Israel diagnosed between 2000 and 2010. Cause of death was classified by TB-specific and non-TB-specific causes. R E S U LT S : During the study period, 451 TB patients died during treatment, representing a CFR of 9.9%. Of these, 72.5% died due to TB-related causes, giving a TBrelated CFR of 7.2%. Both the overall and TB-related CFR decreased over the study period. Risk factors for death included male sex, older age, human immunodeficiency virus coinfection, culture positivity and multidrug-resistant TB (MDR-TB). Patients aged 765 years comprised 70% of the TB-related deaths, and more than half of these (54.9%) were born in the former Soviet Union, Europe (excluding the former Soviet Union) or the USA. C O N C L U S I O N : Both the overall and TB-related CFR decreased over the study period. Physicians who treat older male TB patients with MDR-TB or HIV should increase the index of suspicion to include the possibility of a higher risk of mortality. K E Y W O R D S : case fatality rate; death; Israel; mortality; tuberculosis TUBERCULOSIS (TB) remains a leading cause of mortality worldwide even in the twenty-first century, with 1.4 million deaths in 2011, 1 and is known to cause more than 25% of avoidable adult deaths worldwide. 2 Around 95% of all global TB cases 1 and 98% of TB mortality 3 are reported from developing countries. Compared to developing countries, TB epidemiology is different in most industrialised countries, where TB-related deaths are generally low and are more common among immigrants who originate from countries with high TB prevalence. A meta-analysis reported a TB case-fatality rate (CFR) of 4.2%, 4 and a European surveillance report indicated a TB-related CFR of 8% among European Union countries. 5 TB epidemiology in Israel is similar to that reported from other industrialised countries, as most of TB patients are foreign-born. Over the past 10 years, 86% of all TB patients in Israel have been non-Israeli born, although only 30% of all Israeli citizens are of foreign origin. The Israeli law of return gives Jewish individuals the right to live in Israel and acquire citizenship. Since 1989, more than 1.3 million Israeli citizens have arrived from different countries, some of them TB-endemic, mainly from Ethiopia, and others from the former Soviet Union. 6 These immigrants of Jewish origin are naturalised upon arrival and are entitled to national medical insurance. The migrant population in Israel includes some 200 000 migrant workers who are non-citizens, approximately half of whom are undocumented and not medically insured. 7 TB-related deaths can be reduced by early diagnosis and initiation of effective anti-tuberculosis treatment. 8 As all TB patients in Israel, both citizens and non-citizens, are entitled to free TB diagnostic services and treatment provided by directly observed therapy (DOT) for the entire treatment period, regardless of their medical insurance status, 9 we expected a low CFR.
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The aims of this study were to outline TB mortality trends during treatment, assess TB CFR and identify risk factors associated with mortality during antituberculosis treatment in a country that receives migrants from high TB prevalence countries.
METHODS

Data collection and definitions
This retrospective cohort study included all TB patients in Israel diagnosed between January 2000 and December 2010. TB is a notifiable disease and it is estimated that TB notification in Israel is at 100%. TB treatment distribution is regulated, and is provided only in designated TB clinics or hospitals. 9 TB was defined in this study according to standard World Health Organization (WHO) guidelines. 1 Briefly, a TB patient was defined as a patient with Mycobacterium tuberculosis complex identified using culture from a clinical specimen, or if the TB specialist treating the patient decided to initiate anti-tuberculosis drugs after non-response to 2 weeks of antibiotic therapy in the presence of TB-compatible clinical or radiological findings. All TB patients in Israel receive treatment under DOT for at least 6 months by the TB clinic or the hospital, and are supervised by the regional health departments. During follow-up, patients are recommended to undergo human immunodeficiency virus (HIV) testing, and those treated in the community have monthly follow-up visits to the TB clinic. All specimens are cultured, and drug susceptibility testing is performed for each positive culture by the National TB Reference Laboratory in Tel Aviv.
The Ministry of Health National TB Registry collects data from the regional health departments, all the treating TB clinics, hospitals and the National TB Laboratory. Data include demographic details, clinical characteristics and laboratory findings. Physicians in all TB clinics and hospitals report clinical data to the respective regional health departments, including the final treatment outcome for each patient. TB clinics and hospitals are supervised by the regional health departments, which verify the outcome of each case and facilitate financial reimbursement.
Treatment outcomes were defined according to the WHO/Euro TB categories. 1 Patients who were cured or who completed treatment were considered as 'treatment success'. The outcome was recorded as 'death' if the patient died before commencing or during anti-tuberculosis treatment. The National Deaths Registry was analysed to identify deaths.
To determine the cause of death, clinical charts, death certificates, autopsy information and most recent hospitalisation records of all TB patients who died during treatment were reviewed by a TB specialist. Deaths were classified as 'TB related' where the clinical mode of death, severity of TB disease (based on the presence of systemic symptoms, extent of involvement of affected organs and the central nervous system), occurrence of massive haemoptysis or respiratory, multisystem or specific vital organ failure could be attributed to TB and no other likely cause. 10 'TB-unrelated' deaths were those due to other underlying causes on detailed review of clinical and pathological features by a TB specialist. 11, 12 Countries of birth were divided by the area of origin of the main sources of groups migrating to Israel: America, Africa, the Middle East, Asia, the former Soviet Union and Europe (excluding all areas that were part of the former Soviet Union).
Statistical analysis
The outcome variable was death during treatment, either TB-related or all-cause mortality. Independent variables in this study included demographic characteristics (age, sex and place of birth), medical variables (site of TB, HIV status) and laboratory characteristics (drug resistance and culture results).
Differences in patient characteristics between those who died on treatment and those who did not were analysed using the v 2 test for categorical variables and the Student's t-test for continuous variables or the Mann-Whitney test when assumptions of normality and homogeneity of variances were not met. Statistical significance was set at P , 0.05. Multivariate analysis was performed using logistic regression to identify risk factors predicting death during treatment for TB-related deaths. The model included all independent variables with P , 0.05 in univariate analysis. Results were presented as odds ratios (ORs) and 95% confidence intervals (CIs).
CFR was calculated by dividing the number of deaths by the number of reported cases from the same group. Statistical analysis was performed using SPSS software for Windows, version 17.0 (Statistical Product and Service Solutions, Chicago, IL, USA).
Ethical approval
The study was approved by the Institutional Review Board of the E Wolfson Medical Center (0085-11-WOMC), Holon, Israel.
RESULTS
Between 2000 and 2010, 4555 TB patients were reported in Israel. Of these, 451 (9.9%) died during treatment and 3888 (85.4%) achieved treatment success (1939 were cured and 1949 completed treatment); 5 (0.1%) patients failed treatment, 85 (1.9%) defaulted, 110 (2.4%) were transferred out and 16 (0.3%) individuals were still on treatment at the time of the study ( Figure) .
Of all 451 patients who died during treatment, 327 (72.5%) died from TB-related and 108 (24.0%) from non-TB-related causes. In 16 (3.5%) cases, the cause of death could not be determined, as no data were available. Analysis was restricted to those with known cause of death. Missing cases were analysed and were not significantly different from those who were included in the study in terms of place of birth, age, sex and year of diagnosis (data not shown).
Most deaths during treatment (n ¼ 293, 65.0%) occurred within the first 3 months of the treatment period. The overall CFR during the study period was 9.9% (annual range 6.8-12.1) and CFR due to TBrelated causes was 7.2% (annual range 5.2-10. 56.0%, respectively, P , 0.05). The three most common reasons for death among TB patients who died during treatment from non-TB causes included malignant neoplasms (n ¼ 26, 24.1%), heart disease (n ¼ 21, 19.4%) and septicaemia from pathogens other than M. tuberculosis (n ¼ 13, 12.0%).
The comparison of TB patients who survived and those who died from TB-related causes is shown in Table 1 . Those who died were more likely to be male, aged 765 years, born in Europe or North America, HIV-infected, Israeli citizens, culture-positive and to have multidrug-resistant TB (MDR-TB). In multivariate analysis, male sex, older age, HIV coinfection, culture positivity and MDR-TB were predictive of TB-related death (Table 2 ). Significant risk factors in univariate and multivariate analyses for all-cause mortality were similar to those for TB-related death (results not shown).
TB patients born in Europe or America were significantly older (P , 0.001) than those born elsewhere, followed by patients who were born in the former Soviet Union. Their corresponding CFRs were highest for those born in Europe or America, followed by those born in the former Soviet Union (CFR 17.7% and 7.9%, respectively, Appendix Table) .
DISCUSSION
The overall 11-year mortality of all 4555 TB patients while on treatment in Israel, a country with low TB and HIV prevalence, was 9.9%, with a CFR due to TB-related causes of 7.2%. Risk factors for death included male sex, older age, HIV coinfection, culture positivity and MDR-TB, and were consistent with those reported in other studies. Patients aged 765 years comprised 70% of TB-related deaths; more than half (54.9%) of those aged 765 years were from the former Soviet Union, Europe or America. Most publications have reported lower TB-related CFR and overall CFR than observed in this study. [13] [14] [15] The WHO surveillance report on TB in Europe reported an overall CFR of 6.6% for European Union countries in 2012. 16 A meta-analysis of 22 studies reported a CFR of 3.5% and a TBrelated CFR of 3.0% among HIV-negative TB patients. 4 According to current literature, CFRs are often higher in industrialised countries than in developing countries. 1 This could be explained by the fact that TB generally affects young individuals in developing countries, which are characterised by high transmission rates compared to low-incidence countries, where TB is found among older individuals, often with comorbidities. In our study, 70% of TBrelated deaths occurred in patients aged 765 years, although this older group comprised 27% of all TB patients. Age was a strong risk factor in this study, and has been well documented among TB patients elsewhere. 5, 13, 14, 17, 18 Older age is associated with comorbidities and deteriorated immune response that can contribute to the reactivation of latent tuberculous infection (LTBI). 11 Older age may also be associated with late TB diagnosis due to atypical clinical presentation of symptoms or findings on chest radiography, which may be interpreted as changes related to older age. Due to delayed diagnosis, treatment is postponed, which can complicate morbidity and increase the probability of death. 15, 19, 20 The decrease in age of TB patients in our study was associated with the declining CFR during the study period.
Contrary to some studies, we observed that immigrants born outside Israel are not at higher risk for TB-related death than Israeli-born individuals on multivariate analysis; however, the results indicated a near-significant additional risk for those born in the former Soviet Union. Studies performed in the United States, [21] [22] [23] Mexico, 24 Netherlands, 18 Russia 25 and Australia, 11 and a European surveillance study, 5 found that immigrants had an increased risk of dying from TB. It is likely that immigrants with TB in this study were detected earlier due to active screening programmes for documented immigrants. 26 Since 2001, Israel has been running a pre-departure TB screening programme for eligible immigrants at a health station in Ethiopia, where pulmonary TB cases are diagnosed and treated. 27 Undocumented migrants are screened for TB if they are detained in jail, while documented migrants workers are screened in their countries of origin before being granted an Israeli working visa. Furthermore, migrant workers may have had better health upon arrival to Israel, enjoying the 'healthy immigrant effect'. One theory posits that as those who leave their country of origin are a selfselected population healthy enough to make the arduous trip, they are in better physical condition on arrival than host country inhabitants. 28 Although place of birth was not a risk factor for TB-related death according to multivariate analysis, the CFR among those born in the former Soviet Union, Europe and America (53.8%) was high; we may infer that as this population was older than other patients in our study cohort, the additional risk for place of birth in univariate analysis was adjusted by age in multivariate analysis. In addition to older age, it is possible that the reactivation of LTBI, coupled with other comorbidities, may explain the high CFR. As in other industrialised countries, LTBI prevalence is greater among foreign-born individuals than among the native-born in Israel. 29, 30 LTBI screening in the elderly, especially foreign-born individuals, might therefore be beneficial in preventing active TB, ensuring a timely diagnosis and reducing mortality. Three other risk factors-MDR-TB, HIV and male sex-predicted TB-related death. These factors have also been reported in previous studies. Despite the seemingly low rate of MDR-TB in our study (4.4%), it was still strongly associated with higher rates of death (OR 2.8); this is in line with other studies 15, 17 and a study of 15 industrialised European countries. 5 HIV coinfection has also been previously identified as a risk factor for death in individuals diagnosed with TB. 13 The association of HIV and TB coinfection is often fatal, and the risk of developing TB is estimated to be 21-34 times higher in people living with HIV than among those without HIV infection. 1 The most effective intervention for reducing mortality in HIVinfected TB patients is cotrimoxazole prophylaxis, as recommended by the Joint United Nations Programme on HIV/AIDS in 2000. 31 Finally, higher mortality in males has been reported previously in some studies, 5, 21 but not in others. 11, 22 Theories for the additional risk of death in males include reduced adherence to treatment regimens 32 and a different lifestyle, such as a higher rate of smoking, alcohol use or poor nutrition, 33 ,34 compared to women. This is the first long-term study on TB-related mortality to be published in Israel on an 11-year cohort. The strengths of this study are the inclusion of all cases over a long study period; the study was also able to distinguish between TB-related deaths and allcause mortality by retrieving and reviewing all medical charts. The study is also subject to several limitations. First, TB-related death was determined by inspecting death certificates and medical records collected from various institutions; the quality of these documents varied due to the retrospective nature of the study. Second, information on other reported risk factors, such as comorbidities (chronic obstructive pulmonary disease, diabetes, etc.), alcohol and drug use, unemployment, homelessness, smoking and nutritional factors, 22 were not available. Third, our study did not examine undiagnosed cases of TB, as autopsies in Israel are rarely performed due to religious constraints and cultural norms. 35 Finally, TB-related deaths were determined by a single investigator, although it was based on pre-determined criteria and careful examination of the patients' medical records. 
CONCLUSION
Both overall (9.9%) and TB-related CFR (7.2%) decreased over the study period. Risk factors for death included old age, male sex, MDR-TB and HIV coinfection. Their presence should increase the index of suspicion among treating physicians to the possibility of a higher risk of mortality and facilitate early TB diagnosis and treatment. En el período del estudio fallecieron 451 pacientes tuberculosos durante el tratamiento, lo cual corresponde a una CFR de 9,9%. De estos casos, el 72,5% falleció por causas relacionadas con la TB, y con ello, la CFR relacionada con la TB fue 7,2%. La CFR global y la CFR relacionada con la TB disminuyeron durante el período del estudio. Se observó que los factores de riesgo de mortalidad fueron el sexo masculino, la ancianidad, la coinfección por el virus de la inmunodeficiencia humana (VIH), un cultivo positivo y la TB multidrogorresistente (TB-MDR). Los pacientes de edad de 765 años constituyeron el 70% de los casos de muerte relacionada con la TB y má s de la mitad (54,9%) había nacido en la antigua Unión Soviética, Europa (fuera de la antigua Unión Soviética) o en América. C O N C L U S I Ó N: La CFR y de CFR asociada con la TB disminuyó durante el período del estudio. Los médicos que tratan a los hombres ancianos con TB-MDR o coinfectados por el VIH deben tener presente la posibilidad de un mayor riesgo de mortalidad en estos pacientes.
